The U.S. glaucoma market has seen notable advances in the treatment of OAG following the launches of numerous innovative drugs over the past two years, including Bausch + Lomb’s Vyzulta and Aerie Pharmaceuticals’ Rhopressa and Rocklatan, as well as the highly anticipated launch of Allergan’s bimatoprost SR in 2020. In addition to new drugs, developments have occurred in the field of MIGS in recent years. However, market access decisions for these therapies in Medicare and commercial plans influence ophthalmologists’ prescribing decisions in OAG. Therefore, it is essential for drug marketers and developers to understand how U.S. payers and ophthalmologists react to new treatments entering the highly competitive OAG market.
- Does coverage of therapies for OAG differ on MCOs’ largest Medicare and commercial insurance plans? How are payers covering newer-to-market OAG drugs and FDA-approved devices for MIGS on these plans?
- What clinical and nonclinical factors contribute to a favorable formulary position for a branded OAG therapy?
- How does the market access environment impact ophthalmologists’ prescribing of current therapies for OAG? What areas of drug development in OAG will be most compelling to payers and ophthalmologists?
- How do payers intend to reimburse key emerging therapies bimatoprost SR and DE-117? How will the prescriber landscape evolve in OAG by 2022?
Geography: United States
Primary Research: Survey of 100 U.S. ophthalmologists, survey of 30 U.S. MCO PDs/MDs
Key Drugs Covered: Lumigan, Travatan Z, Combigan, Simbrinza, Alphagan P, Vyzulta, Rhopressa, Rocklatan, Xelpros, bimatoprost SR, DE-117, latanoprost, dorzolamide / timolol
Reimbursement and contracting
Access and prescribing
Opportunities and challenges for emerging therapies
U.S. Access & Reimbursement provides in-depth insight on the impact of payer policy on prescribing behavior so that clients can build their market access strategy and optimize their brand positioning. This analysis of primary market research with physician specialists and U.S. payers helps clients stay up-to-date on restriction policies, gauge payer and prescriber attitudes toward specific therapies, identify opportunities where brands can capture patient share through market access, and maximize opportunities for emerging therapies by learning how previous brands gained favorable reimbursement or why they stumbled.
- Glaucoma - Access & Reimbursement - Detailed, Expanded Analysis (US)
- Access & Reimbursement Glaucoma US August 2019
Author(s): Himanshu Jain, M.S. Pharm
Himanshu joined the CNS / ophthalmology team at Decision Resources Group in 2016. He has authored content for psychiatry and ophthalmology (retinal / nonretinal) indications, including schizophrenia, age-related macular degeneration, diabetic retinopathy / diabetic macular edema, dry eye disease, glaucoma, and uveitis.
Himanshu has more than ten years of experience working in market research and consulting firms, and has managed multiple market assessment projects, including bottom-up forecasts, across multiple therapy areas. He holds a M.S. degree in Pharmacology and Toxicology from the National Institute of Pharmaceutical Education and Research in India and an Executive Post-Graduate Diploma in International Business from the Indian Institute of Foreign Trade.